Application of programmed death 1 inhibitors in Hodgkin lymphoma

VernacularTitle:程序性死亡受体1抑制剂在霍奇金淋巴瘤中的应用
Author: Dandan SHAN ¹ ; Wei LIU ; Dehui ZOU
Author Information

1. 中国医学科学院血液病医院（中国医学科学院血液学研究所）实验血液学国家重点实验室　国家血液系统疾病临床医学研究中心，天津　300020
Keywords: Hodgkin lymphoma; Immune checkpoint inhibitors; Drug therapy, combination; Molecular targeted therapy; Programmed death-1
From: Journal of Leukemia & Lymphoma 2021;30(8):449-454
CountryChina
Language:Chinese
Abstract: The programmed death-1 (PD-1) inhibitor has a unique mechanism and better efficacy in classic Hodgkin lymphoma (cHL). Multiple PD-1 inhibitors have been approved for the salvage treatment of patients with cHL in advanced stage. The combination of PD-1 with other small molecule targeted drugs, immunoactive drugs or cytotoxic drugs can further improve the efficacy and have a better safety compared with the traditional treatment, meanwhile, the regimens have also been explored in treatment of recurrent and refractory patients and frontline therapy. In addition, 9P24.1 amplification, PD-1 ligand expression and circulating tumor DNA level may be potential biomarkers for predicting the efficacy of PD-1 inhibitors.